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Abstract
Background:  Morphine consumption can vary widely between individuals even for identical
surgical procedures. As mu-opioid receptor (OPRM1) is known to modulate pain perception and
mediate the analgesic effects of opioid compounds in the central nervous system, we examined the
influence of two OPRM polymorphisms on acute post-operative pain and morphine usage in
women undergoing elective caesarean delivery.
Results: Data on self-reported pain scores and amount of total morphine use according to patient-
controlled analgesia were collected from 994 women from the three main ethnic groups in
Singapore. We found statistically significant association of the OPRM 118A>G with self-
administered morphine during the first 24-hour postoperative period both in terms of total
morphine (p = 1.7 × 10-5) and weight-adjusted morphine (p = 6.6 × 10-5). There was also significant
association of this OPRM variant and time-averaged self-rated pain scores (p = 0.024). OPRM 118G
homozygotes used more morphine and reported higher pain scores than 118A carriers. Other
factors which influenced pain score and morphine usage include ethnicity, age and paying class.
Conclusion: Our results suggest that ethnicity and OPRM 118A>G genotype are independent and
significant contributors to variation in pain perception and postoperative morphine use in patients
undergoing cesarean delivery.
Background
Studies have consistently demonstrated the existence of
individual differences for both clinical and experimental
pain [1-3]. These include heat-pain sensitivity, responses
to thermal stimuli [4], pressure pain [5], nociceptive stim-
uli [6], and pain related to chronic pain conditions [7].
This interindividual variability is partly heritable, as
reported in studies with twin pairs and animal models [8].
In addition to pain sensitivity and tolerance, clinical stud-
ies indicate that there is extensive interindividual variabil-
ity in drug response and voluntary use of analgesics
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[9,10]. For opioids which are commonly used for both
acute pain and chronic pain, there is wide range in inter-
individual requirement in the use of morphine as demon-
strated by the data from patient-controlled analgesia
(PCA) [11,12]. As patients are in control of the dosage
delivery, the quantity of self-administered analgesics will
be indicative of pain perception and tolerance.
We have previously found an association of the OPRM
118A>G SNP with pain perception and the amount of
morphine self-administered in Chinese patients undergo-
ing the same surgical procedure [13]. In another study, we
found that ethnic Indian patients reported higher pain
and used more morphine compared to Chinese or Malays
[14]. We also previously reported that the frequency of
OPRM 118G allele was higher in Indian compared to
other Asian populations [15]. In the current study, we
investigated the association of two polymorphisms in the
OPRM gene with self-rated postoperative pain and the
amount of self-administered morphine in three main
Asian ethnic groups. In addition, we tested the hypothesis
that OPRM variants and ethnicity are independent predic-
tors of post-operative pain and analgesic consumption.
Methods
Study subjects
This study involved a prospective cohort of women under-
going elective caesarian section under spinal anesthesia at
KK Women's and Children's Hospital. All study proce-
dures were approved by the hospital institutional review
board. Subjects were recruited consecutively over 28
months from May 2005 to August 2007. Written
informed consent was obtained from the patients after the
study was explained to them before the scheduled caesar-
ean procedure.
Study procedure
Data were collected on ethnicity, age, weight, height,
duration of operation, and post-operative vital signs. Sub-
jects were asked to state their ethnicity and that of their
parents and all four grandparents. Information on previ-
ous lower segment cesarean section (LSCS), age, height
and weight was obtained from case records. Before initia-
tion of anesthesia, baseline blood pressure, heart rate, res-
piratory rate, and oxygen saturation by pulse oximetry
were recorded. Intravenous access was then established
with all parturients given 0.5 liter lactated Ringer's solu-
tion for prehydration. Spinal anesthesia was then induced
with a standard single shot at L3-L4 or L4-L5 with the par-
turients in the lateral or sitting position. A 27-gauge pencil
point needle was passed into the subarachnoid space and
free flow of cerebral spinal fluid was ensured before the
intrathecal dose of 2 ml of heavy bupivacaine 0.5% (Mar-
cain, AstraZeneca, Sodertalje, Sweden) and 100 μg of mor-
phine was injected. Surgery was allowed to begin when
sensory block to cold at patients' midline was detected at
T4 level with the patients lying in the supine position with
a 15° left lateral tilt.
Only one patient had had "technical failure" due to
unsuccessful attempts to obtain cerebral spinal fluid with
the spinal needle. Patients who did not obtain sensory
level of >T6 twenty minutes after the administration of
spinal anesthesia were deemed to have a 'failed block'. Six
were converted to general anesthesia due to such "failed
block". All seven were withdrawn from the study.
Antiemetics (IV 4 mg ondansetron, 10 mg metoclopra-
mide, and 4 mg dexamethasone) were administered at the
end of the surgery.
Morphine consumption and side effects
On arrival at the post-anesthesia area, all patients received
an IV patient controlled analgesia pump (PCA) (Rhyth-
mic, Mircel, Greece). The PCA pump was set to deliver one
mg IV bolus of morphine per demand with a lockout time
of five minutes, without continuous background infusion.
The maximum amount of morphine allowed was 10 mg/
hour. The cumulative dose of morphine administered by
each patient within every four-hour period was recorded
until 24 hours post-operation. No other supplemental
analgesics were given during the first 24 hours postopera-
tive period.
Seven patients who had PCA removed before 24 hours
when the last three recordings were not zero, and one
patient who misinterpreted the use of PCA pump were
removed from the study. Another seven patients
requested for withdrawal from the study because they did
not want to continue with PCA.
Other data recorded were nausea and pruritis on a severity
scale of 0–3, 0 = none, 1 = mild, 2 = moderate, 3 = severe;
vomiting as defined by the number of episodes; and respi-
ratory depression as defined by a rate of < 8 and/or shal-
low breathing.
Pain measures
At the postoperative recovery area and at four hourly inter-
vals up to 24 hours counting from the time of administra-
tion of spinal anesthesia, subjects were asked to rate the
degree of pain on the Visual Analogue Scale (VAS) consist-
ing of numeric scale from zero to 10 points; with zero
being "no pain" and 10 being "maximum pain".
Patients who received nitrous oxide by inhalation and/or
IV fentanyl of up to 100 μg were excluded from the study,
as the use of intraoperative opioids and hypnotics could
potentially affect pain scores and the use of PCA mor-
phine postoperatively. Patients who were inadvertentlyMolecular Pain 2009, 5:32 http://www.molecularpain.com/content/5/1/32
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prescribed and took any oral analgesic were also excluded
from the analysis.
Genetic Analysis
At the time of establishing the mandatory intravenous
access before surgery, three ml of blood was collected in
EDTA tubes and stored. DNA was extracted in batches
from frozen whole blood samples using the Gentra Pure-
gene Blood Kit (Gentra Systems Inc., Minneapolis, USA).
DNA was checked for quantity and purity using the Nan-
oDrop Spectrophotometer (NanoDrop Technologies,
Wilmington, USA).
The OPRM A118G polymorphism (rs1799971) was gen-
otyped by the Taqman SNP Genotyping Assay ID
C___8950074_1 (Applied Biosystems, Foster City, USA).
Amplification was performed in a volume of 12 μl con-
taining 25 ng genomic DNA, Taqman Universal Polymer-
ase Chain Reaction Master Mix, 60 nM of each probe, and
270 nM of each primer. Cycling and hybridization condi-
tions were set according to manufacturer's instructions.
The 50 cycles of denaturation and annealing/extension
and post-polymerase chain reaction quantification of flu-
orescent intensity were performed using the Applied Bio-
systems 7300 Real-Time PCR System.
The OPRM -172T>G promoter polymorphism
(rs6912029) was genotyped by allele-specific PCR using
primers CACAGAAGAGTGCCCAGTGA and GAGA-
TACGCCAAGGCATCAGT followed by restriction with
BSe8I at 60°C for hours. Following agarose gel electro-
phoresis, two bands (234 bp and 200 bp) would be
observed for the T allele while the amplicon with the G
allele would be unrestricted and remained as 434 bp.
Statistical Analysis
Summary statistics stratified by the genotypes of the
OPRM118 locus were calculated for all variables. Normal-
ity for each variable was assessed using a Shapiro-Wilk
test. Each variable with distribution that did not deviate
from normality was summarized using the mean and
standard deviation, and comparison across the three gen-
otypes was performed with an analysis of variance
(ANOVA). For variables with skewed distributions, the
median and semi-interquartile range was calculated and
comparison across the three genotypes using the Kruskal-
Wallis rank sum test.
Statistical significance for assessing Hardy-Weinberg equi-
librium for the two OPRM polymorphisms was obtained
using a Monte-Carlo permutation strategy. Multiple linear
regression analysis correcting for race, age, BMI and aver-
age VAS pain score was performed to investigate the effects
of OPRM polymorphisms on morphine intake per kilo-
gram bodyweight. The amount of variance explained by
each covariate was calculated by assessing the sums-of-
squares decomposition in the regression. A separate mul-
tiple linear regression analysis was performed for each of
the three ethnic groups, similarly correcting for age, BMI
and average VAS pain score. Haplotypes for each sample
at the two OPRM polymorphisms were statistically
inferred using an Expectation-Maximization procedure,
and haplotypic effects for the two OPRM polymorphisms
were assessed. All analyses were performed using the sta-




A total of 1066 subjects were recruited. The procedure for
some subjects did not meet study requirement and their
data were removed. Among them there were 24 Chinese,
12 Malays, 11 Indians, 25 mixed ancestry or of races other
than Chinese, Malays and Indians. Results from 994 sub-
jects were included in the analysis. There were 620 Chi-
nese (62.1%), 241 Malays (24.1%) and 137 Indians
(13.7%). The mean age was 32.5 years (SD = 4.8), mean
weight was 70.9 kg (SD = 11.1) and mean height 1.58 m
(SD = 0.06). Six-hundred and ten were private or paying
patients who paid for all surgical and hospitalization
expenses fully while 384 were "non-private" patients who
received co-payment from the government. For 33.6% of
the patients it was the first caesarean delivery. Just over
50% had a prior caesarean delivery, 14.9% had two and
0.9% had three prior caesarean deliveries. Average dura-
tion of operation was 53.7 min (SD = 16.0). There was sta-
tistically significant difference between paying (47.9 ±
13.6 min) and subsidized class (63.1 ± 15.0 min).
The distribution of the genotype and allele frequencies for
the A118G polymorphism (rs1799971) was significantly
different between Chinese and Malays (genotypic: p = 1.0
× 10-7); allelic: p = 1.2 × 10-7, between Chinese and Indi-
ans (genotypic: p = 9.8 × 10-3; allelic: p = 2.0 × 10-3), but
not between Malays and Indians (genotypic: p = 0.374;
allelic: p = 0.201).
Morphine usage and pain measures
The average amount of morphine the patients adminis-
tered on themselves through the PCA pump was 8.95 mg
(SD = 9.59). Sixty-five patients did not use any, 129
patients used only one dose, while another 122 adminis-
tered 2 doses. The highest amount recorded was 62 mg,
followed by 55 mg. The rest were between three and 40
mg.
Average VAS score was 0.594 (SD = 0.591). Two hundred
and thirty-eight patients (23.8%) selected VAS score of
zero for all six four-hourly time points indicating no painMolecular Pain 2009, 5:32 http://www.molecularpain.com/content/5/1/32
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at all during the first 24 hour post-operative period. The
highest time-averaged VAS over the 24-hour period was 4.
Univariate analysis
In a univariate analysis for maximum VAS scores, there
was statistically significant association with both race (p =
4.2 × 10-5) and age (p < 10-3), with Indians and younger
patients reporting higher maximum pain scores. For mean
VAS scores, race (p = 2.1 × 10-7) and age (p = 0.046)
remain significant factors. Paying class was marginally sig-
nificant (p = 0.048) with private patients having lower
mean scores.
For weight-adjusted morphine usage, univariate analysis
revealed that maximum VAS scores had the strongest asso-
ciation (p < 10-16), followed by ethnicity (p = 2.5 × 10-14)
with those of Indian ancestry using the most morphine.
Other statistically significant factors were paying class (p
= 3.7 × 10-6) and age (p = 5.5 × 10-4), with private patients
and those older in age using less morphine.
Association of genetic variants with pain scores and 
morphine use
For VAS scores, there was statistically significant associa-
tion with 118 A>G polymorphism for the time-averaged
VAS scores (p = 0.024) but not across all time-points (p-
values between 0.010 and 0.522) (Table 1). There was
also highly significant difference among the three differ-
ent genotype groups in terms of total morphine self-
administered (p = 1.7 × 10-5) and weight-adjusted mor-
phine (p = 6.6 × 10-5) (Table 1). After correcting for age,
VAS scores and BMI, the association with morphine was
still highly significant (p = 7.85 × 10-3). There was also sta-
tistically significant difference at every time-point (p-val-
ues between 0.039 and 6.8 × 10-7).
For the promoter polymorphism, there was no statistically
significant association with mean and maximum pain
scores or the score at any time-point. There was marginal
association with weight-adjusted morphine used but it
did not reach significance (p = 0.076). Haplotypes con-
sisting of the two polymorphisms were also assessed
although this did not improve the association with the
response variable significantly.
To avoid false association due to allele frequency differ-
ences among different ethnic populations, separate analy-
sis was performed for each of the three different groups.
There was no statistically significant association with the
promoter polymorphism for pain scores or morphine
usage in all three groups (Table 2), but for the 118A>G
polymorphism statistically significant association
remained for Chinese (p = 3.90 × 10-3) but not Malays (p
= 0.085) and Indians (p = 0.804) for morphine usage (Fig
1 and Table 3). For Chinese, there was evidence suggesting
that every additional copy of the G allele results in an aver-
age increase in morphine usage by 0.025 mg (95% CI:
0.012 – 0.038, p = 1.7 × 10-4). The trend was observed in
both Malay and Indian groups (Fig 2), with correspond-
ing increase of 0.014 mg (95% CI: -0.009 – 0.037) and
0.006 mg (95% CI: -0.032 – 0.044), although these results
did not reach statistical significance.
Additional analyses
For OPRM 118 A>G, there was statistically significant
association between genotypes and nausea (p = 0.026) for
all patients (Table 4). This 118G allele was associated with
a reduced risk of nausea in spite of a higher morphine
usage. The AA group had the highest nausea score of 0.033
(SD = 0.006) while the GG group with the lowest at 0.009
(SD = 0.004). The mean for the heterozygous group was
0.029 (SD = 0.006). There was also statistically significant
association of vomiting episodes with this SNP (p =
0.022), again with the AA group having the highest mean
number of episodes at 0.166 (SD = 0.035) while the GG
group with the lowest at 0.117 (SD = 0.042). The mean for
the heterozygous group was 0.117 (SD = 0.042). How-
ever, the association with both variables was not statisti-
cally significant when patients were stratified by ethnicity
with smaller numbers of subjects in each group. There was
Table 1: Association of OPRM 118A>G with different variables
Variable OPRM 118 genotypes p value
AA AG GG
Age (years) 32.4 (4.7) 32.0 (4.8) 32.7 (5.4) 0.19
Height (cm) 157.7 (5.6) 157.5 (5.8) 157.6 (5.4) 0.88
Weight (kg) 70.2 (10.5) 70.9 (11.3) 72.4 (11.6) 0.11
BMI (kg/m2) 28.2 (4.1) 28.6 (4.4) 29.2 (4.5) 6.0 × 10-5
Duration of operation (min) 53.3 (16.3) 54.1 (15.9) 54.0 (15.0) 0.78
Morphine* (total) 4.0 (3.5) 6.0 (5.5) 7.0 (7.0) 1.7 × 10-5
100 × Morphine/kg bodyweight * 5.8 (5.7) 8.8 (8.2) 10.9 (10.3) 6.6 × 10-5
VAS score* (time averaged) 0.29 (0.29) 0.43 (0.36) 0.43 (0.36) 2.5 × 10-2
VAS score* (average of maximum) 1.0 (0.5) 2.0 (0.5) 2.0 (1.0) 0.19
*variables where the median and semi-interquartile range were presented instead of the mean with the standard deviation.Molecular Pain 2009, 5:32 http://www.molecularpain.com/content/5/1/32
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no significant association with pruritis for all patients or
individual ethnic groups.
For OPRM -172 T>G, there was no statistically significant
association between genotypes and nausea, number of
vomiting episodes or pruritis for all patients or within any
ethnic subgroup.
In a multiple regression analysis, the most important fac-
tor contributing to bodyweight-adjusted morphine usage
was maximum pain score (p < 10-16), followed by ethnic-
ity (p = 3.1 × 10-15) and OPRM 118 A>G (p = 5.2 × 10-5).
If the p-value for the association with weight-adjusted
morphine was corrected for OPRM 118 A>G, ethnicity is
still a significant contributing factor (p = 1.1 × 10-10).
Discussion
This study examined the effect of two polymorphisms
within the OPRM gene on pain perception and morphine
usage. The results showed that the 118G variant was asso-
ciated with higher pain scores, higher morphine usage,
and lower nausea score.
Other studies on pain sensitivity have also found that car-
riers of 118G are more sensitive to electrical stimuli and
chemically induced pain [16], and also pressure pain [17].
In terms of analgesic requirement, previous studies have
shown that 118G carriers require higher amount of mor-
phine for cancer pain (n = 99) [18], total knee arthro-
plasty (n = 147) [19], total hysterectomy (n = 80) [20],
and major abdominal surgery [21]. Another study on can-
cer patients also found that those carrying at least one
copy of 118G were poorer responders to morphine [22].
Compared to these studies, our study sample is the most
homogeneous in that it involved patients within a nar-
rower age range who were undergoing the same surgery; it
also had the largest number of subjects. The results
showed the same pattern of higher pain score and mor-
phine usage for 118G carriers among non-laboring
women undergoing caesarean section.
However, one study on labor pain showed that women
carrying the 118G allele of OPRM were more sensitive to
analgesic effect of intrathecal fentanyl [23]. Although this
group is similar to the subjects in our study in terms of
hormones related to pregnancy, the difference is they were
also in labor whereas our patients were not. The authors
of the study suggest that the increased analgesic effect of
the 118G allele could be due to the increased binding in
response to intrathecal fentanyl, or that the mechanism of
spinal and systemic opioid pharmacokinetics may be dif-
ferent; even though the latter was not supported by
another study involving patients who had laparoscopic
abdominal surgery [24]. Another possibility is that the
aspartate substitution in the OPRM receptor resulting
from 118G has different effects on its binding affinity to
morphine and fentanyl due to the structural difference
between the two molecules. However, this would only be
Table 2: VAS and morphine use for the three OPRM -172T>G genotypic groups
VAS (average)* Chinese (n = 610) Malays (n = 238) Indians (n = 135) All (n = 983)
TT (n = 8) 0.14 (0.11) - 1.43 (0.00) 0.14 (0.39)
GT (n = 156) 0.43 (0.43) 0.29 (0.29) 0.57 (0.38) 0.43 (0.36)
GG (n = 819) 0.29 (0.36) 0.43 (0.36) 0.71 (0.43) 0.43 (0.36)
Morphine/kg bodyweight (× 100)*
TT (n = 8) 11.6 (12.6) - 29.4 (11.5) 11.6 (15.4)
GT (n = 156) 5.3 (4.9) 8.1 (5.9) 18.9 (10.2) 6.3 (6.5)
GG (n = 819) 6.3 (6.7) 9.1 (8.5) 15.7 (11.2) 7.8 (8.0)
*Median and semi-interquartile range
Table 3: VAS and morphine use for the three OPRM A118A>G genotypic groups
VAS (average)* Chinese (n = 617) Malays (n = 241) Indians (n = 136) All (n = 994)
AA (n = 389) 0.29 (0.29) 0.43 (0.36) 0.71 (0.36) 0.29 (0.29)
AG (n = 435) 0.43 (0.43) 0.36 (0.29) 0.71 (0.43) 0.43 (0.36)
GG (n = 170 0.43 (0.36) 0.43 (0.29) 0.71 (0.50) 0.43 (0.36)
Morphine/kg bodyweight (× 100)*
AA (n = 389) 4.6 (4.4) 8.1 (6.6) 15.9 (11.7) 5.8 (5.7)
AG (n = 435) 6.6 (7.3) 8.7 (7.8) 15.6 (11.2) 8.8 (8.2)
GG (n = 170) 8.8 (9.3) 10.6 (10.4) 18.2 (15.5) 10.9 (10.3)
*Median and semi-interquartile rangeMolecular Pain 2009, 5:32 http://www.molecularpain.com/content/5/1/32
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plausible if 118G alters the binding affinity and subse-
quent downstream activities of the receptor as suggested
by Bond et al [25]. Recent studies suggest that there is no
difference between the two proteins in terms of binding
affinity, sensitization, internalization or desensitization,
but in vitro studies show that the there is lower expression
of the receptor protein corresponding to the 118G allele
[26-28].
The allele frequencies for the 118G allele for each ethnic
group were similar to what we have found previously with
different sets of subjects from the same three ethnic
groups [15]. In the current study, the frequencies for Chi-
nese were 0.339 compared to 0.351 in that study (p =
0.325), 0.490 compared to 0.450 for Malays (p = 0.306)
and 0.441 compared to 0.474 for Indians (p = 0.450).
These frequencies are similar to the other Asian popula-
tions whose reported range is 0.321 – 0.485 [21,29,30];
significantly higher than the range of 0.074 – 0.200
reported for Caucasian populations [22,30,31].
Due to the observed population difference and to rule out
false association due to ethnic difference in allele frequen-
cies, we have also analyzed the three groups separately.
There was only statistically significant difference for Chi-
nese but not the Malay and Indian subgroups. This could
be due to the smaller number of subjects and the higher
118G frequencies for these two ethnic groups. Our sample
size for Malays had 71% power to detect 20% difference
in additive allelic effect, while our sample size for Indians
had 66% power to detect 20% difference.
VAS score and OPRM 118 genotypes for each of the three  ethnic groups Figure 1
VAS score and OPRM 118 genotypes for each of the 
three ethnic groups.
Mean amount of morphine used (corrected for bodyweight)  and OPRM 118 genotypes for each of the three ethnic  groups Figure 2
Mean amount of morphine used (corrected for body-
weight) and OPRM 118 genotypes for each of the 
three ethnic groups.
Table 4: Association of OPRM A118A>G with nausea and vomiting episodes
Mean nausea score (SD) Chinese (n = 617) Malays (n = 241) Indians (n = 136) All (n = 994)
AA (n = 389) 0.025 (0.096) 0.043 (0.141) 0.062 (0.196) 0.033 (0.006)
AG (n = 435) 0.015 (0.069) 0.044 (0.170) 0.050 (0.156) 0.029 (0.006)
GG (n = 170) 0.012 (0.067) 0.003 (0.022) 0.012 (0.063) 0.009 (0.004)
No. of vomiting episodes (SD)
AA (n = 389) 0.160 (0.702) 0.060 (0.307) 0.360 (0.892) 0.166 (0.035)
AG (n = 435) 0.070 (0.358) 0.150 (0.560) 0.070 (2.004) 0.117 (0.042)
GG (n = 170) 0.060 (0.357) 0 (0) 0.260 (0.378) 0.041 (0.023)Molecular Pain 2009, 5:32 http://www.molecularpain.com/content/5/1/32
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We have previously reported on ethnic difference in VAS
scores for this study group [14]. With VAS included as a
covariate, 118 A>G had the greatest contribution to mor-
phine usage among all the variables, followed by ethnic-
ity, but if VAS was not included as a covariate, then
ethnicity would be the most significant factor, followed
by OPRM. This is potentially impactful because the ethnic
group that had the lowest frequency of 118G (Chinese)
also used the least morphine and reported the lowest pain
scores. Our finding suggests that additional genetic/envi-
ronmental factors apart from 118A>G genotype could be
responsible for the difference in morphine used among
the three ethnic groups. As in our previous study, age and
non-paying status were also predictors of higher pain
scores and greater consumption of morphine for the first
24 postoperative hours. The relationship between
patient's age and epidural/PCA morphine dose has been
well documented [32,33]. The association of pain with
age and surgical complexity was also found in a study on
breast surgery [34]. The association of higher pain scores
with paying status was most likely due to the surgeon's
skills and experience and the duration of operation.
Higher surgical complexity (usually resulting in longer
duration of operation) has also been shown to correlate
with higher pain scores [34].
For the OPRM promoter polymorphism, the TT group
appeared to have the lowest average VAS scores. However,
the number in this group was very small with only six Chi-
nese, two Indians and no Malay having this genotype.
Hence there was considerable uncertainty in the estimated
medians. The potential importance of this SNP is uncer-
tain at this point.
Conclusion
Our results from a standardized acute post-operative pain
model add to the evidence that OPRM 118 genotype
influences the perception of pain and the consequent use
of analgesia. We also found that ethnicity is an important
factor in determining morphine requirement for post-
cesarean analgesic. Identification of predictors could be
important in the provision of post-surgical analgesic with
morphine to provide adequate pain relief while minimiz-
ing the occurrence of side effects.
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